Payment overview · 2025
General Payments
$7,670.48
42 reported records · 12 companies
Healthcare provider profile · identity verified
Robert E Kalb, MD
Allopathic & Osteopathic Physicians|Dermatology · WILLIAMSVILLE, NY · NPI 1750348454
Verified facts
What the public records show
CMS Open Payments records show Robert E Kalb, MD received $7,670.48 in general payments during 2025 across 42 reported records.
Eli Lilly and Company accounted for 31.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Skyrizi, Tremfya.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SKYRIZI as an associated drug or biological on 322790 records involving 36751 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Skyrizi by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported STELARA as an associated drug or biological on 23706 records involving 7279 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Stelara by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TREMFYA as an associated drug or biological on 292917 records involving 40097 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Tremfya by this doctor in 2024.
Janssen Scientific Affairs, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported STELARA as an associated drug or biological on 233 records involving 190 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Stelara by this doctor in 2024.
Janssen Scientific Affairs, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TREMFYA as an associated drug or biological on 4976 records involving 2737 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Tremfya by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Eli Lilly and Company | Unresolved — no canonical attribution shown | $2,400.00 | 31.3% | 1 | 2025 |
| Janssen Scientific Affairs, LLC | Unresolved — no canonical attribution shown | $2,250.00 | 29.3% | 1 | 2025 |
| Celltrion, Inc. | Unresolved — no canonical attribution shown | $1,400.00 | 18.2% | 1 | 2025 |
| The Daavlin Distributing Co | Unresolved — no canonical attribution shown | $1,000.00 | 13.0% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $225.67 | 2.9% | 15 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $136.54 | 1.8% | 12 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $73.38 | 1.0% | 4 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $68.99 | 0.9% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $32.30 | 0.4% | 1 | 2025 |
| Organon LLC | Unresolved — no canonical attribution shown | $31.67 | 0.4% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $27.67 | 0.4% | 1 | 2025 |
| Galderma Laboratories, L.P. | Unresolved — no canonical attribution shown | $24.26 | 0.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Consulting Fee | $7,050.00 | 4 |
| Food and Beverage | $551.49 | 37 |
| Education | $68.99 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TREMFYA Normalized: tremfya |
Drug | Janssen Biotech, Inc., Janssen Scientific Affairs, LLC | $2,318.99 | 2 | 2025 |
Source payment records
|
|||||
| Phothera Phototherapy Devices Normalized: phothera phototherapy devices |
Device | The Daavlin Distributing Co | $1,000.00 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $225.67 | 15 | 2025 |
Source payment records
|
|||||
| SKYRIZI Normalized: skyrizi |
Biological | ABBVIE INC. | $116.83 | 10 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION | $73.38 | 4 | 2025 |
Source payment records
|
|||||
| EBGLYSS Normalized: ebglyss |
Drug | Lilly USA, LLC | $32.30 | 1 | 2025 |
Source payment records
|
|||||
| VTAMA Normalized: vtama |
Drug | Organon LLC | $31.67 | 3 | 2025 |
Source payment records
|
|||||
| CIBINQO Normalized: cibinqo |
Drug | PFIZER INC. | $27.67 | 1 | 2025 |
Source payment records
|
|||||
| RINVOQ Normalized: rinvoq |
Biological | ABBVIE INC. | $19.71 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| SKYRIZI skyrizi |
2025 | Skyrizi | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TREMFYA tremfya |
2025 | Tremfya | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SKYRIZI open payments reported associated product |
CMS Open Payments — General Payments 322790 supporting records · 36751 recipient NPIs · example record 1201352600 |
Skyrizi · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | STELARA open payments reported associated product |
CMS Open Payments — General Payments 23706 supporting records · 7279 recipient NPIs · example record 1174257377 |
Stelara · 2024 Exact normalized brand match · 1 Part D row |
53 | 19 |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | TREMFYA open payments reported associated product |
CMS Open Payments — General Payments 292917 supporting records · 40097 recipient NPIs · example record 1174257364 |
Tremfya · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Janssen Scientific Affairs, LLC Exact reporting entity; no affiliate inference |
2025 | STELARA open payments reported associated product |
CMS Open Payments — General Payments 233 supporting records · 190 recipient NPIs · example record 1174148007 |
Stelara · 2024 Exact normalized brand match · 1 Part D row |
53 | 19 |
| Janssen Scientific Affairs, LLC Exact reporting entity; no affiliate inference |
2025 | TREMFYA open payments reported associated product |
CMS Open Payments — General Payments 4976 supporting records · 2737 recipient NPIs · example record 1174147664 |
Tremfya · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Ketoconazole | Ketoconazole | 148 | 105 |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 111 | 84 |
| Mometasone Furoate | Mometasone Furoate | 98 | 78 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 86 | 74 |
| Metronidazole | Metronidazole | 66 | 46 |
| Methotrexate | Methotrexate Sodium | 60 | 26 |
| Ciclopirox | Ciclopirox Olamine | 57 | 38 |
| Doxycycline Hyclate | Doxycycline Hyclate | 56 | 32 |
| Fluocinonide | Fluocinonide | 54 | 40 |
| Hydrocortisone | Hydrocortisone | 54 | 36 |
| Stelara | Ustekinumab | 53 | 19 |
| Finasteride | Finasteride | 49 | 22 |
| Humira(Cf) Pen | Adalimumab | 47 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 46 | 34 |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 45 | 41 |
| Valacyclovir | Valacyclovir Hcl | 40 | 24 |
| Clindamycin Phosphate | Clindamycin Phosphate | 39 | 25 |
| Calcipotriene | Calcipotriene | 32 | 24 |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 32 | 12 |
| Tretinoin | Tretinoin | 31 | 21 |
| Terbinafine Hcl | Terbinafine Hcl | 29 | 14 |
| Fluorouracil | Fluorouracil | 28 | 24 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 27 | 11 |
| Alclometasone Dipropionate | Alclometasone Dipropionate | 25 | 22 |
| Halobetasol Propionate | Halobetasol Propionate | 24 | 19 |
| Tremfya | Guselkumab | 23 | suppressed |
| Skyrizi Pen | Risankizumab-Rzaa | 22 | suppressed |
| Zoryve | Roflumilast | 21 | 11 |
| Dupixent Pen | Dupilumab | 19 | suppressed |
| Clotrimazole | Clotrimazole | 16 | 13 |
| Fluconazole | Fluconazole | 16 | suppressed |
| Humira Pen | Adalimumab | 16 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 16 | suppressed |
| Taltz Autoinjector | Ixekizumab | 16 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Imiquimod | Imiquimod | 15 | 12 |
| Skyrizi | Risankizumab-Rzaa | 14 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 13 | 13 |
| Cyclosporine Modified | Cyclosporine, Modified | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Thalomid | Thalidomide | 12 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $7,670.48 · 42 records | Eli Lilly and Company | CIBINQO, DUPIXENT, EBGLYSS, OTEZLA, Phothera Phototherapy Devices, RINVOQ, SKYRIZI, TREMFYA, VTAMA | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Skyrizi play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error